Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration...

Ascletis Pharma Inc. announces completion of enrollment in its 13-week U.S. Phase II study (NCT07321678) evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of...

OrthoTrophix, Inc., a privately held biopharmaceutical company, today announced new clinical data demonstrating a significant association between femoral subchondral bone shape, measured by B-score,...

O'Shaughnessy Ventures LLC (OSV), an investment firm that empowers creators, has awarded an O'Shaughnessy Fellowship to Shiwei Mitchell-Wang, a chemist and neuroscientist based in Cambridge,...

The Bristol Myers Squibb-Pfizer Alliance announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to offer Eliquis® (apixaban) on...

Neurocrine Biosciences, Inc. announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial reductions in glucocorticoid (GC) doses...

Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg...

Orthogon Therapeutics announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its...

Avantor, Inc. a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the expansion of its North American...

Baxter International Inc. a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolios, as well as its broad Advanced Surgery...

Ro, the leading direct-to-patient healthcare company, announced eligible patients can now access Foundayo™ (orforglipron) – Eli Lilly Company's newest oral GLP-1 innovation – on the Ro platform, adding...

Dexcel Pharma USA is pleased to announce that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules,...